Evidence map›Paper›PMID 40027944›Full record

ArticleThe journal of liquid biopsy2024

Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-

Lenka N C Boyd, Mahsoem Ali, Jisce R Puik, Annalisa Comandatore, Laura Ginocchi, Laura L Meijer, Rutger-Jan Swijnenburg, Roberta Tartarini, Tessa Y S Le Large, Luca Morelli and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of liquid biopsy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Lenka N C BoydAmsterdam UMC, Location Vrije Universiteit, Department of Surgery, Amsterdam, the Netherlands.
Mahsoem AliAmsterdam UMC, Location Vrije Universiteit, Department of Surgery, Amsterdam, the Netherlands.
Jisce R PuikAmsterdam UMC, Location Vrije Universiteit, Department of Surgery, Amsterdam, the Netherlands.
Annalisa ComandatoreAmsterdam UMC, Location Vrije Universiteit, Department of Medical Oncology, Lab of Medical Oncology, Amsterdam, the Netherlands.
Laura GinocchiDepartment of Oncology, Azienda Sanitaria Locale Toscana Nord Ovest, Massa Carrara Hospital, Massa, Italy.
Laura L MeijerDepartment of Surgery, Erasmus MC-University Medical Center, Rotterdam, the Netherlands.
Rutger-Jan SwijnenburgAmsterdam UMC, Location Vrije Universiteit, Department of Surgery, Amsterdam, the Netherlands.
Roberta TartariniDepartment of Oncology, Azienda Sanitaria Locale Toscana Nord Ovest, Massa Carrara Hospital, Massa, Italy.
Tessa Y S Le LargeAmsterdam UMC, Location Vrije Universiteit, Department of Surgery, Amsterdam, the Netherlands.
Luca MorelliGeneral Surgery Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Ingrid GarajovaMedical Oncology Unit, University Hospital of Parma, Parma, Italy.
Marc G BesselinkCancer Center Amsterdam, Amsterdam, the Netherlands.
Andrea MambriniGeneral Surgery Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Johanna W WilminkCancer Center Amsterdam, Amsterdam, the Netherlands.
Adam E FramptonHPB Surgical Unit, Royal Surrey County Hospital, Guildford, Surrey, UK.
Hanneke W M van LaarhovenCancer Center Amsterdam, Amsterdam, the Netherlands.
Elisa GiovannettiAmsterdam UMC, Location Vrije Universiteit, Department of Medical Oncology, Lab of Medical Oncology, Amsterdam, the Netherlands.
Geert KazemierAmsterdam UMC, Location Vrije Universiteit, Department of Surgery, Amsterdam, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Novel biomarkers, such as plasma microRNAs (miRs), are needed to help guide clinical decision-making for the type of chemotherapy to use in patients with advanced pancreatic ductal adenocarcinoma (PDAC). This study assessed the ability of plasma miRs to predict optimal treatment response from FOLFIRINOX or gemcitabine- Methods: Next-generation sequencing (NGS) was performed for biomarker discovery in pre-treatment plasma samples from advanced PDAC patients subsequently treated with FOLFIRINOX (n = 12) or gemcitabine- Results: In the validation cohort, high plasma miR-379 expression was strongly predictive of treatment response (P Conclusions: Plasma miR-379 appears clinically useful as a predictive biomarker to identify which patients with advanced PDAC benefit most from treatment with FOLFIRINOX or gemcitabine-

Indexed as

FOLFIRINOXGemcitabine-nab-paclitaxelmicroRNAPancreatic ductal adenocarcinomapredictive biomarker

Identifiers

PMID40027944
PMCPMC11863948

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.